Jacobs Levy Equity Management
MTNB icon

Jacobs Levy Equity Management’s Matinas BioPharma MTNB Stock Holding History

Jacobs Levy Equity Management’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-15,095
Closed -$98.1K – 1047
2023
Q3 		$98.1K Buy
+15,095
New +$185K ﹤0.01% 940

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NRS
Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
MSFS
Main Street Financial Solutions Newtown, Pennsylvania $1.34B AUM 19.49% 1-Year Est. Return

Jacobs Levy Equity Management's MTNB Position: Q4 2023 in Review

Jacobs Levy Equity Management sold out of Matinas BioPharma (MTNB) in Q4 2023, closing a stake of 15,095 shares — an estimated $98.1K sold.

Jacobs Levy Equity Management first reported a position in MTNB in Q3 2023 and held it in 1 quarter. The position peaked at $98.1K in Q3 2023. 51 funds tracked by Wall St. Rank hold MTNB as of Q4 2023.

  • Jacobs Levy Equity Management reported no remaining Matinas BioPharma position as of Q4 2023 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 15,095 Matinas BioPharma shares in Q4 2023, an estimated $98.1K.
  • Jacobs Levy Equity Management first reported a position in Matinas BioPharma in Q3 2023 and held it in 1 quarter.
  • Jacobs Levy Equity Management's Matinas BioPharma position peaked at $98.1K in Q3 2023.
  • 51 funds tracked by Wall St. Rank held Matinas BioPharma as of Q4 2023.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2023, filed 14 Feb 2024.